ATE340853T1 - Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung - Google Patents

Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Info

Publication number
ATE340853T1
ATE340853T1 AT01914236T AT01914236T ATE340853T1 AT E340853 T1 ATE340853 T1 AT E340853T1 AT 01914236 T AT01914236 T AT 01914236T AT 01914236 T AT01914236 T AT 01914236T AT E340853 T1 ATE340853 T1 AT E340853T1
Authority
AT
Austria
Prior art keywords
mutant gene
dna vaccination
subunity
adjuvants
asn
Prior art date
Application number
AT01914236T
Other languages
English (en)
Inventor
Young Chul Sung
Sung Hee Lee
Sang Jun Ha
Man Ki Song
Jun Pohang Chang
Original Assignee
Genexine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0012987A external-priority patent/KR100399728B1/ko
Application filed by Genexine Co Ltd filed Critical Genexine Co Ltd
Application granted granted Critical
Publication of ATE340853T1 publication Critical patent/ATE340853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01914236T 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung ATE340853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000013133 2000-03-15
KR10-2001-0012987A KR100399728B1 (ko) 2000-03-15 2001-03-13 ＩＬ-12 활성을 증가시키는 ＩＬ-12ｐ40 소단위체돌연변이 유전자 및 이를 ＤＮＡ 백신 면역증강제로이용하는 용도

Publications (1)

Publication Number Publication Date
ATE340853T1 true ATE340853T1 (de) 2006-10-15

Family

ID=36763001

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914236T ATE340853T1 (de) 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Country Status (10)

Country Link
US (2) US7253151B2 (de)
EP (1) EP1268759B1 (de)
JP (1) JP4180826B2 (de)
CN (1) CN1281748C (de)
AT (1) ATE340853T1 (de)
AU (2) AU2001239581B2 (de)
CA (1) CA2402213C (de)
DE (1) DE60123400T2 (de)
ES (1) ES2272448T3 (de)
WO (1) WO2001068802A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2294213C1 (ru) * 2005-06-27 2007-02-27 Российская академия медицинских наук Государственное учреждение научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова РАМН) Способ вакцинации против гепатита "в" детей со сниженной иммунореактивностью
KR100788930B1 (ko) * 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
WO2007137328A1 (en) * 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated il-12 molecule or chimeric molecules thereof
CN101935687B (zh) * 2009-06-29 2012-11-07 中国科学院上海生命科学研究院 用IL-12p40 siRNA促进肝再生
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US20170291934A1 (en) * 2014-09-22 2017-10-12 Charles C. Reed Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
IL299646A (en) * 2015-12-18 2023-03-01 Oncosec Medical Inc Plasmid templates for heterologous protein expression and methods of use
RS63912B1 (sr) 2016-05-18 2023-02-28 Modernatx Inc Polinukleotidi koji kodiraju interleukin-12 (il12) i njihove upotrebe
AU2017301880C1 (en) 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
CA3083660A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
JP2021512950A (ja) * 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
CN109517052A (zh) * 2018-12-04 2019-03-26 江苏禄亿生生物科技有限公司 一种il-12蛋白突变体及其制备方法和应用、nk细胞培养体系和培养nk细胞的方法
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
EP4448724A4 (de) * 2021-12-17 2025-12-10 Univ Rice William M Verkapselte zellen zur expression von il-12 und verwendungen davon
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
EP0818534A1 (de) * 1996-07-12 1998-01-14 Janssen Pharmaceutica N.V. Menschliche Interleukine-12 Genexpressions-regulierende Sequenzen
US6517839B1 (en) * 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response

Also Published As

Publication number Publication date
AU3958101A (en) 2001-09-24
US7910564B2 (en) 2011-03-22
WO2001068802A3 (en) 2002-02-21
US20040023332A1 (en) 2004-02-05
US7253151B2 (en) 2007-08-07
DE60123400D1 (de) 2006-11-09
CA2402213C (en) 2012-08-07
CN1426464A (zh) 2003-06-25
AU2001239581B2 (en) 2006-01-05
JP4180826B2 (ja) 2008-11-12
DE60123400T2 (de) 2007-08-23
US20070269408A1 (en) 2007-11-22
EP1268759B1 (de) 2006-09-27
EP1268759A4 (de) 2005-09-28
WO2001068802A2 (en) 2001-09-20
JP2003526360A (ja) 2003-09-09
CA2402213A1 (en) 2001-09-20
EP1268759A2 (de) 2003-01-02
ES2272448T3 (es) 2007-05-01
CN1281748C (zh) 2006-10-25

Similar Documents

Publication Publication Date Title
ATE340853T1 (de) Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung
Saljoughian et al. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis
Lin et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis
IL189766A0 (en) Methods for vaccine production and interferon deficient substrates
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
Gherardi et al. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
CA2397675A1 (en) Altered strain of the modified vaccinia virus ankara (mva)
ATE366586T2 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
Chhajer et al. Genetically modified organisms and visceral leishmaniasis
Franková et al. IFN‐γ‐induced TNF‐α is a prerequisite for in vitro production of nitric oxide generated in murine peritoneal macrophages by IFN‐γ
ATE414761T1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
Calarota et al. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine
ATE354370T1 (de) Inaktivierte immunogene bakterielle ganzzell- zusammensetzungen
JP2004533846A5 (de)
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
TWI601742B (zh) 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
HUP0402548A2 (hu) Madárembrió-részecskékből álló biomassza vírusantigének előállítására
McGhee et al. IL-12 Is an Effective Adjuvant for Induction
Martínez-Sobrido et al. The Specialized Proresolving Mediator
RU2005104190A (ru) Способ изготовления ассоциированной инактивированной культуральной вакцины против инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота
UA41237A (uk) Спосіб виготовлення вакцинальних алергенів

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties